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Abstract: Influenza B is responsible for a significant proportion of the global morbidity, mortality
and economic loss caused by influenza-related disease. Two antigenically distinct lineages co-
circulate worldwide, often resulting in mismatches in vaccine coverage when vaccine predictions fail.
There are currently operational issues with gold standard serological assays for influenza B, such
as lack of sensitivity and requirement for specific antigen treatment. This study encompasses the
gold standard assays with the more recent Pseudotype-based Microneutralisation assay in order to
study comparative serological outcomes. Haemagglutination Inhibition, Single Radial Haemolysis
and Pseudotype-based Microneutralisation correlated strongly for strains in the Yamagata lineage;
however, it correlated with neither gold standard assays for the Victoria lineage.
Keywords: influenza B viruses; serology
1. Introduction
Influenza is a respiratory syndrome caused by three of six genera in the Orthomyx-
oviridae family, influenza A, B and C. A fourth genus (Influenza D) has also been charac-
terised [1]. Influenza A virus is the most widespread; its various subtypes are classified
according to their antigenically variable surface glycoproteins: haemagglutinin (HA, H1-
H18) and neuraminidase (NA, N1-N11).
Influenza B viruses comprise two co-circulating, antigenically distinct lineages that
diverged from their progenitor, strain B/Hong Kong/8/1973, into the “Yamagata-like”
(B/Yamagata/16/1988 type) and “Victoria-like” (B/Victoria/2/1987 type) lineages [2].
This human virus causes a significant proportion (20–30%) of global morbidity associated
with influenza virus disease due to its global distribution and unpredictable switches in
the predominating lineage circulating [3–5]. The WHO vaccine recommendations include
an up-to-date strain from both lineages for quadrivalent vaccines, but only one for trivalent
vaccines. Should the circulating lineage not match the predicted lineage, there is an
inevitable drop in coverage against influenza B-linked disease [3,6–8]. In the United States,
multiple quadrivalent vaccines have been approved and are in use [9].
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1.1. Serological Assays for Influenza B
Single Radial Immuno-Diffusion (SRID) has been one of the mainstays for the identi-
fication and characterisation of inactivated influenza vaccines, correlating with immuno-
genicity and clinical benefit/protection [10–17]. Haemagglutination Inhibition (HI) has
been used for many decades as the tool used for the detection of influenza antibodies [18].
These assays, in combination with ELISA [19] and Single Radial Haemolysis (SRH) [20]
comprise the gold standard assays for detection of influenza virus targeting antibodies and
are generally applicable to the B type. However, more recent work has highlighted distinct
shortcomings of the traditional assays, focusing research on the development of novel
assays utilising various different technologies [21–30]. Ether treatment has been employed
for influenza B viruses, prior to HI experiments, raising the efficacy of the HI test to that of
the Complement Fixation (CF) test [31–33]. This technique was developed due to the lack
of reactivity of certain strains of influenza, as well as the B type. Alongside the adaptation
of SRID to influenza B resulting in SRH, historical use of ether treatment was found to
increase sensitivity but reduces the specificity of HI during assay of serum samples against
influenza B [20,31,32,34–37]
1.2. Monoclonal Antibodies
Monoclonal antibodies (mAbs) are increasingly being used in influenza research,
whether for development of standards to complement or validate assays, or more directly
to evaluate Haemagglutinin (HA) epitopes targeted through vaccination, or as potential
therapeutics, as seen in the recent Ebola outbreak [38,39]. The mAbs employed in this
study were developed as an antibody-based alternative for influenza B identity (Yamagata
or Victoria lineages) and potency assays [40].
1.3. Study Aims
This study’s goal is determining the correlation of the gold standard assays HI and SRH
with the recently adapted influenza B Pseudotype-based Microneutralisation assay (pMN),
as HI detects primarily receptor binding site (RBS) proximal antibodies while SRH detects
IgG1, IgG3 and IgM class antibodies that are compatible with the complement cascade.
pMN detects HA-neutralising antibodies directed against both the globular head and the
stalk [41]. As with SRH, HI has been correlated with protection against influenza, with
titres at or above 40 linked to 50% or greater protection from infection in adults [12,42–44].
Linking either of these assays with pMN, despite the detection of different types of antibody,
would allow more confidence to be attributed to the results generated using this assay,
despite it actually detecting neutralisation of the function of the influenza HA glycoprotein.
Correlation data between assays is important for in-depth interpretation of immunogenicity
data, especially when correlation is determined with an assay that has been used for in vivo
or challenge studies, establishing a correlate of protection. By inter-comparison of assays
utilising different approaches, the scientific community can make more informed decisions
on the future direction of vaccine design and testing. To date, no study of this type has been
performed using influenza B, with efforts focusing more on the predominant A type [45,46].
As a major contributor to morbidity and mortality, it is essential to interrogate the correlations
and relationships between data produced for influenza B using a range of assays. This is
especially important as this type is lacking a definitive reservoir and circulates yearly as part
of two lineages. In this study, influenza B lentiviral pseudotypes (PV) will be interrogated
using a defined set of mAbs and a panel of sera, to put this resource to use in the correlation
of pMN, SRH and HI.
2. Materials and Methods
2.1. Plasmids
Expression plasmid phCMV1 bearing the HA gene for B/Hong Kong/8/1973,
B/Yamagata/16/1988 and B/Florida/4/2006 were obtained from Dr Davide Corti,
Institute for Research in Biomedicine, Bellinzona, Switzerland. B/Victoria/60/2008,
Vaccines 2021, 9, 100 3 of 18
B/Brisbane/60/2008 and B/Bangladesh/3333/2007 HA genes were subcloned into plas-
mid pI.18. Plasmids p8.91 and pCSFLW were obtained from Prof. Greg Towers, University
College, London, and originate from gene therapy applications [47,48]. To achieve matu-
ration of HA gene products, protease-encoding plasmids were used [49–52], as detailed
in Table 1 alongside the quantity transfected per well of a 6-well plate. Information
regarding the strains of influenza B used can also be found in Table 1.
Table 1. Influenza B strains, accession numbers, lineage, protease type and quantity required for
production in 6-well format are displayed. Human Airway Trypsin (HAT) and Transmembrane
protease, serine 4 (TMPRSS4) expression plasmids were co-transfected with other plasmids to allow
maturation of HA0 to HA1/2 inside producer cells.
Strain Accession Lineage Protease ng per 6-Well
B/Hong Kong/8/1973 K00425 Pre-split HAT 125
B/Victoria/2/1987 FJ766840 Victoria HAT 125
B/Brisbane/60/2008 KX058884 Victoria TMPRSS4 125
B/Yamagata/16/1988 CY018765 Yamagata HAT 125
B/Florida/4/2006 EU515992 Yamagata HAT 125
B/Bangladesh/3333/2007 CY115255 Yamagata HAT 250
2.2. Serum Samples
One serum set was used per lineage of influenza B, consisting of samples taken pre
and post seasonal vaccination. Paired low and high responders (based on HI results)
were chosen. In total, 41 pairs of sera were assayed against B/Brisbane/60/2008 and
43 pairs against B/Florida/04/2006. Anonymised serum samples were obtained from
Italian subjects and in compliance with Italian ethics law.
2.3. Pseudotype Production
Lentiviral pseudotypes were produced by transient transfection of HEK293T/17
cells with lentiviral packaging construct plasmids p8.91 [48] and pCSFLW [47] alongside
an influenza B glycoprotein expression plasmid and corresponding protease expression
plasmid as described in Section 2.1. Cells were transfected with 500 ng HA expression
plasmid and corresponding protease listed in Table 1, alongside 500 ng p8.91 and 750 ng
pCSFLW per well in a 6-well format. After 8 h, media was replaced and 1 unit of ex-
ogenous neuraminidase (Clostridium perfringens, Sigma, St. Louis, MO, USA) added per
well to enable HA-pseudotype release. Cell culture supernatants were harvested 48 h
post-transfection, filtered at 0.45 µm and titrated for transduction-based (firefly) luciferase
activity on HEK293T/17 cells in 96-well format (Supplementary Figure S1).
2.4. Pseudotype-Based Microneutralisation Assay
Serial (1:2) dilutions of serum were performed in 96-well format in a total volume
of 50 µL, and 50 µL of lentiviral pseudotype added to give a total relative luminescence
(RLU) output of 1 × 106 RLU per well. Serum and virus were incubated for 1 h at 37 ◦C,
5% CO2 in a humidified incubator, then 1.5 × 104 HEK293T/17 cells were added per well.
Plates were then incubated at 37 ◦C, 5% CO2 in a humidified incubator for 48 h, whereupon
50 µL of Bright-Glo (Promega) reagent was added per well and luminescence read after a
5 min incubation period. Data points were normalised to 100% and 0% neutralisation plate
controls, and non-linear regressional analysis was performed to obtain neutralisation curves
and IC50 and IC90 values. R2 values of 0.8 or more were used as a cut-off for confidence in
the titration of antibody response, and any samples below this were discarded.
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2.5. Haemagglutination Inhibition Assay
The influenza viruses used in the HI were B/Brisbane/06/2008 (15/146) and
B/Florida/04/2006 (08/138), obtained from the National Institute for Biological Stan-
dards and Control (NIBSC), United Kingdom. Serum samples were pre-treated with
receptor destroying enzyme (RDE) from Vibrio cholerae (Sigma Aldrich) at 1:5 ratio for
18 h at 37 ◦C in a water bath and then heat-inactivated for 1 h at 56 ◦C in a water bath
with 8% sodium citrate at a 1:4 ratio. Turkey erythrocytes (Emozoo S.N.C, Casole d’Elsa,
Italy) were centrifuged twice, washed with a saline solution (0.9%) and adjusted to a final
dilution of 0.35%. RDE-treated serum samples were diluted two-fold with saline solution
(0.9%) in a 96-well plate, starting from an initial dilution of 1:10. 25 µL of influenza virus
was added to each well, and the mixture was incubated at room temperature for 1 h. At
the end of the incubation, erythrocytes were added and the plates were evaluated for
the inhibition of agglutination after 1 h at room temperature.
The antibody titre was expressed as the reciprocal of the highest serum dilution showing
complete inhibition of agglutination. Since the starting dilution was 1:10, the lower limit
of detectable antibody titre was 10. When the titre was below the detectable threshold, the
results were conventionally expressed as 5 for calculation purposes, half the lowest detection
threshold. Geometric mean titers were calculated from experimental repeats.
2.6. Single Radial Haemolysis Assay
The influenza viruses B/Brisbane/06/2008 (15/146) and B/Florida/04/2006 (08/138)
were obtained from the NIBSC. Serum samples were heat-inactivated at 56 ◦C for 30 min
in a water bath. Turkey erythrocytes were centrifuged twice and washed with phosphate-
buffered saline (PBS). Diluted virus was added to the erythrocyte suspension at a concen-
tration of 2000 haemagglutination units (HAU) per mL. The erythrocyte–virus suspension
was incubated at 4 ◦C for 20 min, and subsequently, a solution of 2.5 mM Chromium
Chloride (CrCl3) was added to the suspension, and it was incubated at room temperature
for 10 min. The suspension was then carefully mixed once and then centrifuged. A stock
solution consisting of 1.5% agarose in PBS containing 0.1% sodium azide and 0.5% low
gelling agarose was prepared. This agarose stock solution was maintained at 45 ◦C in
a water bath. The final suspension of erythrocytes, virus and guinea pig complement
was vigorously shaken and evenly spread onto each plate. Plates were incubated at room
temperature for 30 min and then stored at 4 ◦C for 30–90 min. Holes were introduced into
each plate with a calibrated punch, and 6 µL of each serum sample was dispensed into
each hole. The plates were stored in a humid box and incubated at 4 ◦C for 16–18 h in the
dark. Subsequently, plates were incubated in a water bath at 37 ◦C for 90 min; diameters of
the areas of haemolysis were then read in mm with a calibrating viewer [20,53].
2.7. mAbs and Controls
Influenza B mAbs were kindly provided by Dr Jerry P Weir, Division of Viral Products,
Food and Drug Administration (FDA), USA [40]; see Table 2. Anti-B/Brisbane/60/2008
HA serum (11/136) was obtained from the NIBSC and employed against all strains of
influenza B as a serum positive control. This antiserum had previously been tested in our
laboratory, showing that it was capable of neutralising all available strains of influenza B
to varying degrees, with the highest potency against the matched B/Brisbane/60/2008
strain [54].
Table 2. Influenza B mAbs. Five mAbs used, two specific for each lineage of influenza B and one
binding to an epitope conserved between both lineages (cross).
mAb 2F11 3E8 1H4 8E12 5A1
Target lineage Cross Yamagata Yamagata Victoria Victoria
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2.8. Statistical Analysis
Mean endpoint antibody titres (or IC50 for pMN) for each serum sample were com-
pared between assays. This comparison was carried out in GraphPad Prism where a
two-tailed Pearson’s correlation was performed on pairs of data sets that were plotted
against each other. A line of best fit was used in order to show the general trend of correla-
tion between data sets. Analysis was performed between pre- (V1) and post-vaccination
(V2) sera, and fold change from V1 to V2. pMN data consisted of both IC50 and IC90 values,
and further analysis was carried out on transformed (log10) V2 data.
3. Results
3.1. Lineage Specific and Cross-Reacting mAbs Neutralise Influenza B PV
Lineage-specific mAbs neutralised all influenza B PV except B/Brisbane/60/2008,
which was not susceptible in our experiments. This PV was unaffected by either the Victoria
specific mAbs, or the 2F11 cross-lineage mAb. Despite this, anti-B/Brisbane/60/2008
HA serum showed the highest neutralisation against the matched B/Brisbane/60/2008
pseudotypes (IC50 > 256,000) (Figure 1). The 2F11 mAb neutralised Yamagata lineage strains
the strongest (IC50: 2–4 ng/mL), followed by the pre-lineage strain B/Hong Kong/8/1973
(IC50: 8 ng/mL) and finally the Victoria strain B/Victoria/2/1987 (IC50: 160 ng/mL).
Yamagata lineage-specific mAbs 3E8 and 1H4 were only effective on Yamagata lineage PVs,
neutralising B/Bangladesh/3333/2007, the strongest (IC50: 3 and 4 ng/mL, respectively),
followed by B/Florida/4/2006 (IC50: 21 and 3 ng/mL) and B/Yamagata (IC50: 34 and
6 ng/mL). Victoria-specific mAbs 8E12 and 5A1 neutralised B/Hong Kong the strongest
(IC50: 2 and 4 ng/mL, respectively), followed by B/Victoria/2/1987 (IC50: 47 and 22). See
Table 3 for a list of IC50 values.




Figure 1. Anti-B/Brisbane/60/2008 HA serum (11/136, NIBSC) neutralises matched and related 
strains B/Brisbane/60/2008 and B/Victoria/2/1987 the strongest but also neutralises Yamagata line-
age strains and the B/Hong Kong/7/1973 precursor to a lesser extent. 
The data for the Victoria lineage viruses show reduced antibody potency, with IC50 val-
ues up to 20 times higher. Victoria epitope targeting mAbs neutralise B/Victoria as well as the 
Hong Kong precursor. Neutralisation curves for the above data are shown in Figures 2–4. 
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This PV is neutralised strongly by Victoria-specific mAbs 5A1, 8E12 and cross-lineage mAb 2F11 
but not Yamagata specific mAbs 3E8 or 1H4. 
Figure 1. Anti-B/Brisbane/60/2008 HA serum (11/136, NIBSC) neutralises matched and related
strains B/Brisbane/60/2008 and B/Victoria/2/1987 the strongest but also neutralises Yamagata
lineage strains and the B/Hong Kong/7/1973 precursor to a lesser extent.
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Table 3. IC50 values in ng/mL for the neutralisation of 6 strains of influenza B HA-PV by mAbs. Pre-lineage strain, Yamagata
and Victoria lineages highlighted in grey, green and blue, respectively. With the exception of B/Brisbane/60/2008, the cross
lineage mAb 2F11 acts as expected, neutralising all influenza B PV. Yamagata specific mAbs neutralise PV bearing HAs
from Yamagata lineage strains, while Victoria-specific mAbs neutralise PV bearing HAs from Victoria lineage strains with
the exception of B/Brisbane/60/2008. The pre-lineage spli t strain B/Hong Kong/8/1973 is neutralised in a Victoria-like
manner by 2F11 and Victoria lineage-specific mAbs 8E12 and 5A1.
mAb Target B/HongKong/8/1973 B/Florida/4/2006 B/Bangladesh/3333/2007 B/Victoria/2/1987 B/Brisbane/60/2008
2F11 Cross 8 3 2 4 -
3E8 Yamagata - 34 21 3 -
1H4 Yamagata - 6 3 4 -
8E12 Victoria 2 - - - -
5A1 VIctoria 4 - - - -
Anti B/Brisbane/60/2008 polyclonal sheep serum was used as an anti-influenza B
control in all of these experiments and for all strains of influenza B PV due to its ability to
neutralise all strains tested in the pMN assay, regardless of lineage. This antiserum is most
potent against the homologous strain B/Brisbane/60/2008 and the other Victoria lineage
strain B/Victoria/2/1987 (Figure 4), and 100% neutralisation is seen from 1:200 up to the
penultimate dilution point 1:128,000.
The data for the Victoria lineage viruses show reduced antibody potency, with IC50
values up to 20 times higher. Victoria epitope targeting mAbs neutralise B/Victoria as
well as the Hong Kong precursor. Neutralisation curves for the above data are shown in
Figures 2–4.
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Figure 2. pMN neutralisation curves for FDA mAbs 2F11, 3E8, 1H4, 8E12 and 5A1 against PV bearing
the HA glycoprotein from the influenza B pre-lineage split strain, B/Hong Kong/8/1973. This PV
is neutralised strongly by Victoria-specific mAbs 5A1, 8E12 and cross-lineage mAb 2F11 but not
Yamagata specific mAbs 3E8 or 1H4.
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Figure 4. pMN neutralisation curves for FDA mAbs 2F11, 3E8, 1H4, 8E12 and 5A1 against PV bearing HA glycoproteins from
Yamag t lineage strains B/Yamagata/16/1988, B/Florid /4/2006 and B/Bangladesh/3333/2007. Potent neutralisation
by Yamagata specific mAbs 3E8 and 1H4, and by cross-lineage mAb 2F11. No neutralisation is observed for Victoria
lineage-specific mAbs 8E12 and 5A1.
3.2. Correlation of SRH, HI and pMN
SRH, HI and pMN data for strains B/Florida/04/2006 (Y magata) and B/Brisb ne/60/2008
(Victoria) were analysed to assess the correlation between each assay. Endpoint titres for high
responders (V2) are displayed in Figure 5. The titre profiles of each serum set are very similar
between the two viruses, despite each virus having its own unique set of sera. HI values
range from 5 to 1280 for both B/Brisbane/60/2008 and B/Florida/04/2006, with arithmetic
means at 156 and 270, respectively. SRH values range from 37 to 106 and 38 to 99 mm2 for
B/Brisbane/60/2008 and B/Florida/04/2006, respectively. Arithmetic means were 58 and
57 mm2, respectively. pMN (IC50) values ranged from 4594 to 209,395 for B/Brisbane/60/2008
and 3349 to 31,954 for B/Florida/04/2006. Arithmetic mean pMN titre means were 41,613 and
11,740, respectively.
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0.0001). V1 results weakly correlated (r = 0.32, p = 0.0375) for SRH and HI, and more so for 
V2 results (r = 0.39, p = 0.0123). See Figures 6 and 7 for correlation graphs and data. 
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Upon transformation of the V2 data to a log10 scale, correlation was still not observed 
between pMN and SRH or HI despite normalization of scales, with a weak correlation 
between the latter two (r = 0.35, p = 0.0189). pMN IC90 data correlated weakly with HI and 
SRH (r = 0.37 and 0.45, p = 0.00188 and 0.0026, respectively). The correlation seen was 
reduced by a transformation of IC90 data and comparison on a log scale (r = 0.23 and 0.32, 
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3.5. Correlation of Data: B/Florida/4/2006 IC50 
In contrast to the results for B/Brisbane/60/2008, pMN data correlated well with SRH 
and HI, and V2 SRH and HI correlated strongly (r = 0.79, p ≤ 0.0001) (see Figure 11). For 
the fold change data, pMN correlated with HI and SRH (r = 0.66 and 0.56, p ≤ 0.0001). SRH 
and HI correlated strongly (r = 0.72, p ≤ 0.0001) (see Figure 12). For V2 data, pMN corre-
lated with SRH (r = 0.46, p = 0.0023) and HI (r = 0.61, p ≥ 0.0001). 
3.6. Correlation of Data: B/Florida/4/2006 IC90 and Transformed Data 
Transformation to a log10 scale caused a slight reduction in the significance attributed 
to the correlation between pMN and SRH or HI (r = 0.57 or 0.30, p = 0.0002 or 0.0555), but 
correlation remained strong between all three assays. IC90 data correlated very well between 
pMN and SRH or HI (r = 0.85 and 0.65, p ≤ 0.0001) and this was maintained when data were 
transformed to the log10 scale (r = 0.78 and 0.62, p ≤ 0.0001) (see Figures 13–15).
Figure 5. Haemagglutination Inhibition (HI), Single Radial Haemolysis (SRH) endpoint titres and pMN IC50 values for
high responders (V2) against B/Brisbane/60/2008 and B/Florida/04/2006. Titres displayed show similar profiles for each
strain tested, with a broader range of pMN IC50 values for B/Brisbane/60/2008.
3.3. Correlation of Data: B/Brisbane/60/2008 IC50
Two different sets of values for each assay were correlated, V2 data (post-vaccination
high responders) and fold change between V1 and V2. For B/Brisbane/60/2008, no correla-
tion was observed between pMN and the other assays, with Pearson’s r values ranging from
−0.07 to −0.08 (p = 0.13 to 0.9). SRH and HI correlated when fold changes were compared
(r = 0.224, p = 0.1539) and increased after the removal of two outliers (r = 0.60, p ≥ 0.0001).
V1 results weakly correlated (r = 0.32, p = 0.0375) for SRH and HI, and more so for V2 results
(r = 0.39, p = 0.0123). See Figures 6 and 7 for correlation graphs and data.Vaccines 2021, 9, x FOR PEER REVIEW 9 of 21  
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Figure 6. Correlation of SRH, HI and pMN (IC50) mean V2 values assayed against B/Brisbane/60/2008 PV. Pearson’s two-tailed analysis performed using GraphPad Prism. 
No correlation was observed between IC50 antibody titres and SRH or HI (Pearsons r = 0.009 and -0.152, respectively). SRH and HI values were correlated (Pearsons r = 
0.38). p > 0.05 = ns, p ≤ 0.05 = *. 
Figure 6. Correlation of SRH, HI and pMN (IC50) mean V2 values assayed against B/Brisbane/60/2008 PV. Pearson’s two-tailed
analysis performed using GraphPad Prism. No correlation was observed between IC50 antibody titres and SRH or HI (Pearsons
r = 0.009 and −0.152, respectively). SRH and HI values were correlated (Pearsons r = 0.38). p > 0.05 = ns, p ≤ 0.05 = *.
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3.4. Correlation of Data: B/Brisbane IC90 and Transformed Data
Upon transformation of the V2 data to a log10 scale, correlation was still not observed
between pMN and SRH or HI despite normalization of scales, with a weak correlation
between the latter two (r = 0.35, p = 0.0189). pMN IC90 data correlated weakly with HI
and SRH (r = 0.37 and 0.45, p = 0.00188 and 0.0026, respectively). The correlation seen was
reduced by a transformation of IC90 data and comparison on a log scale (r = 0.23 and 0.32,
p = 0.132 and 0.0372, respectively) (see Figures 8–10).




Figure 8. Correlation of transformed (log10) SRH, HI and pMN (IC50) mean V2 values assayed against B/Brisbane/60/2008 PV. Pearson’s two-tailed analysis performed 
using GraphPad Prism. Weak correlation was observed between log SRH and HI values (Pearsons r = 0.36). No correlation was observed between log IC50 antibody titres 
and log HI or SRH values (Pearsons r = −0.196 and 0.007, respectively). p > 0.05 = ns, p ≤ 0.05 = *.
Figure 8. Correlation of transformed (log10) SRH, HI and pMN (IC50) mean V2 values assayed against B/Brisbane/60/2008
PV. Pearson’s two-tailed analysis performed using GraphPad Prism. Weak correlation was observed between log SRH and
I values (Pearsons r = 0.36). No correlation was observed between log IC50 antibody titres and log HI or SRH values
(Pearsons r = −0.196 and 0.007, respectively). p > 0.05 = ns, p ≤ 0.05 = *.Vaccines 2021, 9, x FOR PEER REVIEW 12 of 21  
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against B/Brisbane/60/2008 PV. Pearson’s two-tailed analysis performed using GraphPad Prism. Weak correlation was 
observed between log IC90 antibody titres and log HI or SRH values (Pearsons r = 0.23 and 0.32, respectively). p > 0.05 = ns, 
p ≤ 0.05 = *. 
 
Figure 10. Correlation of pMN (IC90) with HI and SRH using mean V2 values for sera assayed against B/Brisbane/60/2008 PV. 
Pearson’s two-tailed analysis performed using prism Graph Pad. Weak correlation was observed between IC90 antibody titres 
and HI (Pearsons r = 0.36). IC90 values correlated well with SRH values (Pearsons r = 0.45). p ≤ 0.05 = *, p ≤ 0.01 = **.
Figure 9. Correlation of transformed (log10) dat for pMN (I 90) ith HI and SRH using mean V2 value for sera assayed
against B/Brisbane/60/2008 PV. Pearson’s two-tailed analysis performed using GraphPad Prism. Weak correlation was
observed between log IC90 antibody titres and log HI or SRH values (Pearsons r = 0.23 and 0.32, respectively). p > 0.05 = ns,
p ≤ 0.05 = *.
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Figure 10. Correlation of p N (IC90) with HI and SRH using mean V2 values for sera assayed against B/Brisbane/60/2008
PV. Pearson’s two-tailed analysis performed using prism Graph Pad. Weak correlation was observed between IC90 antibody
titres and HI (Pearsons r = 0.36). IC90 values correlated well with SRH values (Pearsons r = 0.45). p ≤ 0.05 = *, p ≤ 0.01 = **.
3.5. Correlation of Data: B/Florida/4/2006 IC50
In contrast to the results for B/Brisbane/60/2008, pMN data correlated well with
SRH and HI, and V2 SRH and HI correlated strongly (r = 0.79, p ≤ 0.0001) (see Figure 11).
For the fold change data, pMN correlated with HI and SRH (r = 0.66 and 0.56, p ≤ 0.0001).
SRH and HI correlated strongly (r = 0.72, p ≤ 0.0001) (see Figure 12). For V2 data, pMN
correlated with SRH (r = 0.46, p = 0.0023) and HI (r = 0.61, p ≥ 0.0001).
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Figure 11. Correlation of SRH, HI and pMN (IC50) mean V2 values assayed against B/Florida/4/2006 PV. Pearson’s two-tailed analysis performed using GraphPad Prism. 
Weak correlation was observed between IC50 antibody titres and SRH (Pearsons r = 0.46). Strong correlation was observed between IC50 antibody titres and HI (Pearsons r 
= 0.61), as well as between SRH and HI (Pearsons r = 0.79) for the V2 data tested. p ≤ 0.01 = **, p ≤ 0.0001 = ****. 
  
Figure 11. Correlation of SRH, HI and pMN (IC50) mean V2 values assayed against B/Florida/4/2006 PV. Pearson’s
two-tailed analysis performed using GraphPad Prism. Weak correlation was observed between IC50 antibody titres and
SRH (Pearsons r = 0.46). Strong correlation was observed between IC50 antibody titres and HI (Pearsons r = 0.61), as well as
between SRH and HI (Pearsons r = 0.79) for the V2 data tested. p ≤ 0.01 = **, p ≤ 0.0001 = ****.
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Figure 12. Correlation of SRH, HI and pMN (IC50) V1 to V2 fold change values assayed against B/Florida/4/2006 PV.
Pearson’s two-tailed analysis performed using GraphPad Prism. Strong correlation was seen between fold change in pMN
and HI values between V1 and V2 antibody titres (IC50), Pearsons r = 0.65. pMN and SRH V1/V2 fold changes correlated
well, Pearsons r = 0.55 and strong correlation was observed for V1/V2 fold change for antibody titres of SRH and HI
(Pearsons r = 0.72). p ≤ 0.001 = ***, p ≤ 0.0001 = ****.
3.6. Correlation of Data: B/Florida/4/2006 IC90 and Transformed Data
Transformation to a log10 scale caused a slight reduction in the significance attributed
to the correlation between pMN and SRH or HI (r = 0.57 or 0.30, p = 0.0002 or 0.0555),
but correlation remained strong between all three assays. IC90 data correlated very well
between pMN and SRH or HI (r = 0.85 and 0.65, p ≤ 0.0001) and this was maintained when
data were transformed to the log10 scale (r = 0.78 and 0.62, p ≤ 0.0001) (see Figures 13–15).




Figure 13. Correlation of transformed (log10) SRH, HI and pMN (IC50) mean V2 values assayed against B/Florida/4/2006 PV. Pearson’s two-tailed analysis performed using 
GraphPad Prism. Strong correlation is observed between log SRH and HI (Pearsons r = 0.62. log pMN and log HI correlate well (Pearsons r = 0.56), and weak correlation 
was seen between log pMN and log SRH (Pearsons r = 0.30). p > 0.05 = ns, p ≤ 0.001 = ***, p ≤ 0.0001 = ****.
Figure 13. Correlation of transformed (log10) SRH, HI and pMN (IC50) mean V2 values assayed against B/Florida/4/2006
PV. Pearson’s two-tailed analysis performed using GraphPad Prism. Strong correlation is observed between log SRH and
HI (Pearsons r = 0.62. log pMN and log HI correlate well (Pearsons r = 0.56), and weak correlation was seen between log
pMN and log SRH (Pearsons r = 0.30). p > 0.05 = ns, p ≤ 0.001 = ***, p ≤ 0.0001 = ****.
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Figure 15. Correlation between pMN (IC90) with SRH and HI mean V2 values, assayed against B/Florida/4/2006 PV.
Pearson’s two-tailed analysis performed using GraphPad prism. Strong correlation was observed between IC90 antibody
titres and HI or SRH, with Pearsons r values of 0.85 and 0.64, respectively. p ≤ 0.0001 = ****.
4. Discussion
Neutralisation of influenza B bearing PV with influenza B-specific mAbs was consistent,
with the exception of B/Brisbane/60/2008 PV. Victoria-lineage-specific mAbs neutralised the
type B/Victoria/2/1987 PV, while Yamagata-lineage-specific mAbs neutralised Yamagata
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lineage strains (Figures 1–3). The cross-lineage-specific mAb 2F11 neutralised both lineages
as well as the pre-lineage split strain B/Hong Kong/8/1973. Discordant correlation was
observed between Victoria and Yamagata lineages, with the former correlating well between
pMN, SRH and HI and the latter only correlating, weakly, between SRH and HI.
4.1. Neutralisation by Influenza B mAbs
While the majority of influenza B mAbs generated by the FDA neutralised the expected
strains in the pMN assay, neutralisation was not seen for B/Brisbane/60/2008 by Victoria-
specific mAbs, in contrast to data supporting the characterisation of these mAbs [40].
One possible explanation for this is N-linked glycosylation masking epitopes on
the HA surface. The presence or absence of a glycosylated residue would dramati-
cally affect results when neutralising with a mAb targetting one specific epitope. In
this study, a WT B/Brisbane/60/2008 gene was used to produce PV for use in pMN, while
B/Victoria/2/1987 was human-codon-optimised. HI and SRH made use of inactivated
antigen produced in bacteria, whereas Verma and colleagues used a combination of ELISA
using inactivated antigen and PV assays, with the latter using an egg-adapted strain of
B/Brisbane/60/2008. Studies on egg-adaptation of influenza B viruses have characterised
mutations within the 190 helix loop of the receptor-binding domain, which led to a signifi-
cant change in antigenicity of the HA [55,56] due to the loss of an N-linked glycosylation
site [57]. Despite the lack of neutralisation shown against B/Brisbane/60/2008 by the
Victoria-specific mAbs in this study, polyclonal hyperimmune antisera produced against
the same HA subtype was the most effective at neutralising it (Figure 4), suggesting that the
HA itself is antigenically correct and that the problem lies in the specific epitopes targeted
by 8E12 and 5A1. These mAbs were reported to bind to the amino acid residues 241 and
203, respectively, which are within or close to the 190 helix, which spans from residue 195
to 235 [40,58].
The fact that mAbs specific for the Victoria lineage also neutralised the pre-lineage
split strain (Figure 1) is not surprising, as fewer structural differences have been reported
between these than between the pre-lineage strain and the Yamagata lineage. The positions
of escape mutations generated against the Victoria lineage-specific mAbs 8E12 and 5A1
presented in their characterisation were P241Q and K203R, respectively [40]. These are
present within the 190 helix (RBD) of Victoria strains, which is very similar in amino acid
composition to the 190 helix of the pre lineage split strain B/Hong Kong/8/1973 [58].
4.2. Correlation between SRH and HI
Overall, SRH and HI correlated strongly across both lineages, except for in V1 samples,
which were predictably very low due to the lower sensitivity of these assays. As most of
the V1 samples were negative in terms of HI and SRH data, they were clustered around the
respective titres of 5 and 4 mm2, which led to a lack of correlation through analysis. Fold
change and V2 samples correlated for both Victoria and Yamagata lineages, indicating that
increases in influenza B HA-specific antibodies are detected by both assays.
4.3. Correlation between pMN and SRH
pMN correlated strongly with SRH for the Yamagata lineage strain, with correlation
observed for all data sets except for the negative or low titre samples that clustered to the
lower detection limit of SRH at 4 mm2. This suggests that pMN would be preferable for
the evaluation of low-response samples, as its sensitivity offers an advantage over SRH.
For B/Brisbane/60/2008, however, the only correlation observed was between IC90 values
(transformed and raw data). Despite this, Pearson’s r was still below 0.5 in each case.
4.4. Correlation between pMN and HI
As with pMN and SRH, a strong correlation is seen for the Yamagata strain
(Figures 6–10) but not the Victoria strain (Figures 8–12); once again, B/Brisbane/60/2008 only
poorly correlates when analysis is performed using IC90 values (Figure 10). B/Brisbane/60/2008
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IC50 antibody titres do not correlate with SRH or HI when using either fold-change or V2 data,
transformed or raw.
4.5. Limitations of This Study
Influenza B viruses have not undergone the ether treatment that could enhance their
performance in the HI assay, despite reducing the assay specificity. The pseudotype-based
assay represents a novel platform that is increasingly used by laboratories worldwide.
However, each assay and antigen requires validation and optimization before this assay
can compete with traditional HI or MN assays, which remain the gold standard for im-
munological outputs. In addition, as this was a single-cycle assay, the effect of neutralising
or interfering antibodies on viral egress was not measured, contrary to live virus assays
such as MN or PRNT, where an effect can be measured on viral egress. In our hands, the
B/Brisbane/60/2008 PV did not perform as expected against characterised monoclonal
antibodies, despite being strongly neutralised by polyclonal serum raised against the same
antigen. This was a small panel of mAbs that would benefit from being expanded and
evaluated on B/Brisbane/60/2008.
5. Conclusions
The results presented in this study, while discordant in regards to B/Brisbane/60/2008
PV, still represent the first comprehensive study correlating HI, SRH and pMN assays
for influenza B serology. Lentiviral pseudotypes are becoming increasingly popular as a
surrogate for live virus neutralisation assays—especially in current R&D using containment
level 3 or 4 pathogens such as SARS-CoV-2 and Ebolavirus. The exquisite sensitivity of
this assay allows the differentiation of serum samples that would otherwise be categorized
as negative in the gold standard assays. This sensitivity can be a double-edged sword,
as serum samples and reference antisera against the influenza B lentiviral pseudotypes
reported in this study were strongly neutralising, leading to exceptionally high IC50 titers
that may have been an overestimation of the serum potency. The nature of each assay
described in this study is unique and detects antibodies that may interfere at different
points in the virus life cycle. Neutralising antibodies are among the most important and
often the goal for universal vaccine approaches—but are not explicitly detected by older
assays including SRH and ELISA.
Many efforts have been made to standardise assays between platforms and labora-
tories to facilitate the comparison of different projects and data sets, such as the efforts
by the Consortium for the Standardization of Influenza Seroepidemiology (CONSISE,
https://consise.tghn.org/) and the establishment of reference standards and calibrants by
the National Institute for Biological Standards and Control (NIBSC, nibsc.org). Until each
pseudotyped virus has been fully validated and compared to traditional microneutralisa-
tion in a parallel and controlled setting, the gold standard assays will remain preferable for
laboratories that are able to perform live virus assays.
Supplementary Materials: The following are available online at https://www.mdpi.com/2076-3
93X/9/2/100/s1, Figure S1: Titration of luciferase pseudotypes bearing the B/Brisbane/60/2008
haemagglutinin on HEK293T/17 cells. Quality control and production optimisation can be found as
described previously.
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